India, Sept. 26 -- Clearmind Medicine Inc. (CMND), a clinical-stage biopharmaceutical company, announced this week the publications of three U.S. patents covering certain proprietary drug combinations to treat a range of mental health disorders. The proprietary, novel combinations contain lysergic acid diethylamide (LSD), ketamine, and ibogaine with N-acylethanolamines such as palmitoylethanolamide (PEA). The various mental health indications treated by these therapies include depression, post-traumatic stress disorder (PTSD), and substance use disorders. Clearmind stated that the patents expand the intellectual property developed through its collaboration with NeuroThera Labs (NTLX). NeuroThera's PEA technology is being integrated with the...